<DOC>
	<DOCNO>NCT01999972</DOCNO>
	<brief_summary>Despite success anti-angiogenic therapy multiple treatment setting , fraction patient refractory vascular endothelial growth factor ( VEGF ) inhibitor treatment , majority patient eventually develop evasive resistance . It propose mesenchymal-epithelial transition factor ( c-MET ) ligand hepatocyte growth factor ( HGF scatter factor ) contribute VEGF inhibitor resistance , combine c-MET inhibitor VEGF inhibitor provide additional clinical activity compare VEGF inhibitor alone . This hypothesis test use cMET/ALK inhibitor , crizotinib , combination VEGF inhibitor , axitinib.Since first study axitinib give combination crizotinib , study primarily assess safety tolerability combination regimen .</brief_summary>
	<brief_title>A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Diagnosis Dose Escalation Phase : Histologically cytologically confirm diagnosis advance solid tumor resistant standard therapy standard therapy available . Diagnosis Dose Expansion Phase : Histologically cytologically confirm advanced RCC component clear cell subtype Dose Expansion Phase : least one measureable lesion define RECIST [ Response Evaluation Criterion Solid Tumors ] version 1.1 . ECOG [ Eastern Cooperative Oncology Group ] Performance Status 0 1 . Major surgery &lt; 4 week radiation therapy &lt; 2 week patient registration . History known active seizure disorder , brain metastasis , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease . Dose Expansion Phase : diagnosis malignancy within 2 year prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Carcinoma</keyword>
	<keyword>Renal Cell</keyword>
</DOC>